Investigation of the Optimal Interval of Perioperative Serum Flomoxef Administration in Hepatobiliary-Pancreatic Surgery-Reference-Cited by-同舟云学术

Investigation of the Optimal Interval of Perioperative Serum Flomoxef Administration in Hepatobiliary-Pancreatic Surgery

Published:2025-04-20 Issue:2 Volume:92 Page:196-203
ISSN:1345-4676
Container-title:Journal of Nippon Medical School
language:en
Short-container-title:J Nippon Med Sch

Author:

Takayama Yoko¹²,Komatsu Toshiaki³,Tsumuraya Satomi⁴,Kubo Hidefumi⁵,Nishizawa Nobuyuki⁵,Tajima Hiroshi⁵,Kaizu Takashi⁵,Otori Katsuya⁶,Okamoto Hirotsugu⁷,Kumamoto Yusuke⁵,Hanaki Hideaki⁸

Affiliation:

1. Department of Infection Control and Infectious Diseases, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine

2. Department of Infection Control and Prevention, Kitasato University Hospital

3. Department of Pharmacy, Kitasato University Hospital

4. Sogo Medical Company Limited

5. Department of General-Pediatric-Hepatobiliary Pancreatic Surgery, Kitasato University School of Medicine

6. Pharmacy Practice and Science I, Research and Education Center for Clinical Pharmacy, Kitasato University School of Pharmacy

7. Department of Anesthesiology, Kitasato University School of Medicine

8. Infection Control Research Center, The Omura Satoshi Memorial Institution, Kitasato University

Publisher

Medical Association of Nippon Medical School

Link

https://www.jstage.jst.go.jp/article/jnms/92/2/92_JNMS.2025_92-211/_pdf

Reference33 articles.

1. 1. Darlow CA, da Costa RMA, Ellis S, et al. Potential antibiotics for the treatment of neonatal sepsis caused by multidrug resistant bacteria. Paediatr Drugs. 2021 Sep;23 (5):465-84. doi: 10.1007/s40272-021-00465-z

2. 2. Shionogi & Co., Ltd.. [FLUMARIN^® for Intravenous Injection/Kits] [Internet]. Osaka: Shionogi & Co., Ltd.; 2023 Nov. [cited 2023 Nov]. Available from: http://med.shionogi.co.jp/products/medicine/flumarin/interview-form_pdf.html. Japanese.

3. 3. Bassetti M, Peghin M, Pecori D. The management of multidrug-resistant Enterobacteriaceae. Curr Opin Infect Dis. 2016 Dec;29 (6):583-94. doi: 10.1097/QCO.0000000000000314

4. 4. Willyard C. The drug-resistant bacteria that pose the greatest health threats. Nature. 2017 Feb 28;543 (7643):15. doi: 10.1038/nature.2017.21550

5. 5. Chong Y, Shimoda S, Shimono N. Current epidemiology, genetic evolution and clinical impact of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Genet Evol. 2018 Jul;61:185-8. doi: 10.1016/j.meegid.2018.04.005